好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Prospective open-label study of Nusinersen treatment for adults with Spinal Muscular Atrophy
Neuromuscular and Clinical Neurophysiology (EMG)
S5 - Therapeutics in ALS and SMA (2:28 PM-2:39 PM)
009

There is paucity of safety and efficacy data on nusinersen treatment of adults with SMA as well as the safety and tolerability of alternative methods for intrathecal delivery of the drug in patients with spinal fusions. Additionally, it is unknown whether restoring SMN levels will improve motor unit repair in adult SMA patients undergoing treatment with nusinersen. While there is dramatic improvement seen in infants with SMA, it is not clear whether restoring high levels of SMN in adult SMA patients will result in improved reinnervation capacity of the remaining motor units and thus improved muscle strength. 

To determine the tolerability and efficacy of nusinersen in adults with SMA and to explore its effect on motor unit physiology.

Adults with SMA were prospectively studied prior to and after initiation of nusinersen. Baseline and post treatment data included muscle strength  measured using maximum voluntary isometric contraction (MVICT), motor function assessed using six minute walk test, Hammersmith Functional Motor Scale Expanded (HFMSE), Revised Upper Limb Module (RULM), SMA-Function Rating scale (SMAFRS), pulmonary function, and Ulnar-CMAP and MUNE.   

A total of 40 patients were evaluated for nusinersen treatment. Treatment was decline by 17 % due to lack of data and concerns about the intrathecal procedure. The majority of those interested in treatment (80%) received insurance approval or enrolled in free drug program. Currently 25 patients (12 women, 13 men, mean age 38 ±12.5; range, 18-65) received total of 120 injections. Fluoroscopy guided C1-C2 lateral approach was used for 8 patients with spinal fusion who received 35 injections. 

We successfully administered nusinersen to a large cohort of adults with SMA. Data on outcome analysis will be presented at the meeting.  

.

Authors/Disclosures
Bakri Elsheikh, MD, FAAN (The Ohio State University Wexner Medical Center)
PRESENTER
Dr. Elsheikh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen . Dr. Elsheikh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Argnex . The institution of Dr. Elsheikh has received research support from Biogen. The institution of Dr. Elsheikh has received research support from Cure SMA.
No disclosure on file
William D. Arnold, MD Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for La Hoffmann Roche. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cadent Therapeutics . Dr. Arnold has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Dr. Arnold has received research support from NIH. The institution of Dr. Arnold has received research support from NMD Pharma. The institution of Dr. Arnold has received research support from Gilead Sciences. The institution of Dr. Arnold has received research support from CureSMA. Dr. Arnold has received intellectual property interests from a discovery or technology relating to health care.
Stephen J. Kolb, MD, PhD (The Ohio State University) Dr. Kolb has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for AveXis. Dr. Kolb has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for CureSMA. The institution of Dr. Kolb has received research support from NIH. The institution of Dr. Kolb has received research support from AveXis. The institution of Dr. Kolb has received research support from NIH.
John T. Kissel, MD, FAAN Dr. Kissel has nothing to disclose.